Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Perkins Capital Management Inc.

Perkins Capital Management Inc. lowered its stake in Moderna, Inc. (NASDAQ:MRNA) by 13.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,375 shares of the company’s stock after selling 1,000 shares during the period. Perkins Capital Management Inc.’s holdings in Moderna were worth $426,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of MRNA. Cedar Wealth Management LLC grew its holdings in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the period. Commerzbank Aktiengesellschaft FI grew its holdings in Moderna by 1.7% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after acquiring an additional 93 shares during the period. CVA Family Office LLC grew its holdings in Moderna by 21.6% during the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after acquiring an additional 96 shares during the period. Claro Advisors LLC boosted its position in Moderna by 2.0% during the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after purchasing an additional 108 shares in the last quarter. Finally, McAdam LLC boosted its position in Moderna by 1.1% during the second quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after purchasing an additional 117 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $51.81 on Thursday. The firm has a market capitalization of $19.92 billion, a P/E ratio of -3.37 and a beta of 1.69. The stock has a fifty day moving average price of $63.00 and a 200 day moving average price of $99.97. Moderna, Inc. has a 52 week low of $49.60 and a 52 week high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CFO James M. Mock sold 1,321 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James M. Mock sold 715 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,184 shares of company stock worth $238,531 over the last three months. 15.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on MRNA shares. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Piper Sandler decreased their target price on Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, September 13th. Sanford C. Bernstein started coverage on Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price on the stock. Jefferies Financial Group decreased their target price on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday, October 15th. Finally, The Goldman Sachs Group reduced their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $94.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.